Sign up to save your podcasts
Or
Share Hannah Linden, MD, Highlights AMEERA-1 for ER+/HER2- mBC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Hannah Linden, MD, Highlights AMEERA-1 for ER+/HER2- mBC
Dr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.
View all episodes
By HMP GlobalDr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.